Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 17/20 | 0.44 |
| ▸ | PDE1A | P54750 | 16/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 16/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107030 | 0.90 | CHRNA7 (0.44) | PDE1BPDE1APDE1CMPOTLR8 | |
| SCHEMBL4106788 | 0.86 | PDE1B (0.47) | PDE1BPDE1APDE1CTLR8TLR7 | |
| SCHEMBL4096139 | 0.83 | PDE1B (0.46) | PDE1BPDE1APDE1C | |
| SCHEMBL4097630 | 0.82 | P2RX7 (0.45) | MPOTLR8TLR7 | |
| SCHEMBL4103467 | 0.78 | MPO (0.41) | MPOTLR8TLR7 | |
| SCHEMBL4108287 | 0.78 | DCPS (0.48) | MPOTLR8TLR7 | |
| SCHEMBL4102866 | 0.78 | MPO (0.43) | MPOTLR8TLR7 | |
| SCHEMBL4107202 | 0.77 | MPO (0.39) | MPOTLR8TLR7 | |
| SCHEMBL4107871 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL4096527 | 0.77 | CHRNA7 (0.43) | PDE1BPDE1APDE1CTLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | claimed |
| US-8338435-B2 | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | PNPO, PNP, DPYD | PDE1B 1290/4885PDE1A 1305/4885PDE1C 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.